Recruiting Studies
Advanced SearchData: ClinicalTrials.gov · Source of record for eligibility and locations
Top Cities for Retinitis Pigmentosa Clinical Trials
Retinitis Pigmentosa clinical trials are recruiting across 125 cities. Here are the cities with the most active studies:
Retinitis Pigmentosa Trial Phases
80 research organizations are sponsoring retinitis pigmentosa trials.
About Retinitis Pigmentosa
Retinitis pigmentosa (RP) is a group of inherited retinal diseases that cause progressive loss of photoreceptor cells in the retina, leading to vision loss. It typically begins with night blindness and progresses to tunnel vision. Gene therapy and retinal implants are areas of active research.
Clinical trials are advancing new treatments for retinitis pigmentosa. Currently, 89 studies are recruiting a combined 26,276 participants across the United States. Research is being conducted by 80 organizations including Société Internationale d'Urologie, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), The American Porphyrias Expert Collaborative and 77 others.
2026 Retinitis Pigmentosa Research Landscape
As of July 2026, the retinitis pigmentosa clinical trial landscape includes 89 actively recruiting studies across 125 cities in the United States. These studies are collectively seeking 26,276 participants, with an average enrollment target of 295 per study.
The research spans multiple phases of development: 26 studies are in NA, 23 studies are in PHASE2, 22 studies are in PHASE1, 8 studies are in PHASE3, 2 studies are in PHASE4. The presence of Phase 3 trials indicates that some retinitis pigmentosa treatments are in late-stage testing and may be approaching regulatory review.
Research is being led by 80 different organizations, including Société Internationale d'Urologie, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), The American Porphyrias Expert Collaborative, Merck Sharp & Dohme LLC, National Institute of Allergy and Infectious Diseases (NIAID), and 75 others. The large number of sponsors reflects significant research interest and investment in retinitis pigmentosa treatment advancement.
Geographically, retinitis pigmentosa trials are most concentrated in Los Angeles, California (12 trials); Boston, Massachusetts (12 trials); New York, New York (10 trials); Philadelphia, Pennsylvania (10 trials); San Francisco, California (8 trials) and 7 other cities.
Featured Retinitis Pigmentosa Studies
Highlighted recruiting studies for retinitis pigmentosa, selected by enrollment size and research scope.
BPH Global Registry
Benign prostatic hyperplasia (BPH) is one of the most common performed surgical procedures in urology. Over the past few decades there have been an increasing development of newer surgical treatment options. Additionally, the outcome parameters for BPH treatments have been standardized. While data are available for the initial pivotal studies, post-market release data are lacking. Under the umbrel...
Natural History Study of Patients With Excess Androgen
This study will evaluate and gather information in patients with genetic causes of too much androgen (male-like hormone) in order to better understand the effects of too much androgen and describe problems associated with it. Too much androgen in childhood, if untreated, results in rapid growth and early puberty with early cessation of growth and short stature in adulthood. Too much androgen in ad...
Longitudinal Study of the Porphyrias
The objective of this protocol is to conduct a longitudinal multidisciplinary investigation of the human porphyrias including the natural history, morbidity, pregnancy outcomes, and mortality in people with these disorders.
Frequently Asked Questions About Retinitis Pigmentosa Clinical Trials
Are there retinitis pigmentosa clinical trials near me?
Yes, there are 89 retinitis pigmentosa clinical trials currently recruiting across 125+ cities in the United States, including Los Angeles, California; Boston, Massachusetts; New York, New York. Browse the studies above to find one at a location convenient for you.
How do I join a retinitis pigmentosa clinical trial?
To join a retinitis pigmentosa clinical trial: 1) Browse the available studies on this page, 2) Click on a study that interests you, 3) Check the study locations to find a site near you, 4) Review the eligibility criteria, and 5) Contact the study site or complete the eligibility form. The process is free and you can withdraw at any time.
Are retinitis pigmentosa clinical trials free?
Yes, participation in retinitis pigmentosa clinical trials is free. Study-related treatments, medical tests, and doctor visits are provided at no cost to participants. Many studies also offer compensation for your time and travel expenses.
What types of retinitis pigmentosa treatments are being studied?
Current retinitis pigmentosa clinical trials are testing a range of approaches across NA (26 studies), PHASE2 (23 studies), PHASE1 (22 studies), PHASE3 (8 studies), PHASE4 (2 studies). These include new drugs, combination therapies, medical devices, and other interventions sponsored by 80 research organizations.
Is it safe to participate in retinitis pigmentosa clinical trials?
Clinical trials are carefully regulated by the FDA and institutional review boards (IRBs). All trials must follow strict safety protocols, and participants receive close medical monitoring throughout the study. You can withdraw from a trial at any time without penalty.
Data updated July 16, 2026 from ClinicalTrials.gov
About This Data
Data: ClinicalTrials.gov · Source of record for eligibility and locations
Clinical trial information on this page is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health (NIH) and National Library of Medicine (NLM). Study data is refreshed every hour to ensure accuracy.
Medical Disclaimer: The information provided on this page is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making decisions about clinical trial participation or changes to your treatment plan.
Page reviewed by the HelloStudys Research Team · Last updated July 16, 2026 · Data from ClinicalTrials.gov